Advertisement

Topics

Search Results for "Rituximab Patent"

21:09 EST 24th November 2017 | BioPortfolio

Matching Channels

CD20 Antibodies

The chimeric anti-CD20 antibody rituximab (Rituxan & MabThera) from Biogen Idec and Genentech/Roche is one of the world’s commercially most successful antibodies (2007 sales of over US$ 5 bl...

Biosuperior Antibodies

After biosimilar versions of therapeutic proteins have become reality in Europe and in the US, now it’s the turn of therapeutic antibodies to be in the line of fire. Patents of the first wave of...

India

India, in the Asian subcontinent is the world’s fourth largest producer of pharmaceuticals, and is thought as one of the most promising biotech markets in the world. Several important steps ...

Tumor Necrosis Factor TNF Products

Tumor Necrosis Factor (TNF) and TNF receptor antagonists and agonists used to treat TNF-mediated inflammatory diseases such as rheumatoid arthritis or to treat cancer. TNF blockers are the commerc...

Matching News

Celltrion and Teva set to take lead in US rituximab biosimilars

Celltrion and Teva look set to get a biosimilar of Roche’s blockbuster MabThera/Rituxan (rituximab) onto the US market ahead of rivals. Rituximab went off patent in the US last year, leaving it op...

Biocad expects Indian approval of rituximab biosimilar soon

India’s Central Drugs Standard Control Organization (CDSCO) has recommended AcellBia, the first rituximab…

Positive phase I results for rituximab biosimilar CT-P10 in patients with rheumatoid arthritis

Rituximab is an established anti-CD20 monoclonal antibody used for the treatment of some haematological cancers and immune-mediated diseases, such as rheumatoid arthritis (RA). CT-P10 (Truxima) is the...

Obinutuzumab vs. Rituximab for Diffuse Large B-Cell Lymphoma

Substituting obinutuzumab for rituximab during induction chemotherapy did not improve outcomes.

Roche under pressure as second rituximab biosimilar filed in US

The pressure is mounting on Roche after Swiss rival Sandoz filed a US biosimilar of cancer and inflammatory diseases drug rituximab, closely behind a rival from Teva and Celltrion. Rituxan (rituximab...

Obinutuzumab vs Rituximab in FL: 'Too Close to Call'

Obinutuzumab for induction and maintenance provides significantly higher PFS than rituximab, the current standard of care for follicular lymphoma (FL). But an editorial cautions it's too soon to tell....

Rituximab or irradiation promotes IL-17 secretion and thereby induces resistance to rituximab or irradiation

EC approval for three rituximab biosimilars

On 13 July 2017, three rituximab biosimilars, Blizima, Rituzena (previously Tuxella) and Ritemvia, received European Commission (EC) approval.

Matching PubMed Articles

Patent Highlights April-May 2017.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

A novel classification method for aid decision of traditional Chinese patent medicines for stroke treatment.

Traditional Chinese patent medicines are widely used to treat stroke because it has good efficacy in the clinical environment. However, because of the lack of knowledge on traditional Chinese patent m...

Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis.

The addition of rituximab to standard chemotherapy has significantly improved survival in patients with lymphoma. Recently, maintenance therapy with rituximab has been shown to prevent relapse and pro...

Off-label use of rituximab in autoimmune disease in the Top End of the Northern Territory, 2008-2016.

Rituximab, an anti-CD20 B cell depleting monoclonal antibody, is increasingly prescribed off-label for a range of autoimmune diseases. There has not previously been an audit of off-label rituximab use...

Network characteristics and patent value-Evidence from the Light-Emitting Diode industry.

This study proposes a different angle to social network analysis that evaluates patent value and explores its influencing factors using the network centrality and network position. This study utilizes...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement